Karyopharm Therapeutics Q2 2024 GAAP EPS $(0.20) Beats $(0.30) Estimate, Sales $42.786M Beat $36.179M Estimate
Karyopharm Therapeutics Q2 2024 GAAP EPS $(0.20) Beats $(0.30) Estimate, Sales $42.786M Beat $36.179M Estimate
karyopharm therapeutics 2024年第二季度的GAAP每股收益爲$(0.20)，超過了$(0.30)的估計，銷售額爲4278.6萬美元，超過了3617.9萬美元的估計。
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.30) by 33.33 percent. This is a 31.03 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $42.786 million which beat the analyst consensus estimate of $36.179 million by 18.26 percent. This is a 13.86 percent increase over sales of $37.579 million the same period last year.
Karyopharm Therapeutics（納斯達克:KPTI）報告每股虧損$(0.20)，超過分析師預期的$(0.30)的33.33％。這是相對於去年同期每股虧損$(0.29)的31.03％增長。該公司報告季度銷售額爲4278.6萬美元，超過分析師預期的3617.9萬美元的18.26％。這是相對於去年同期的銷售額3757.9萬美元的13.86％增長。